Intraoperative radiation therapy delivered prior to lumpectomy for XXXX : a single institution study.

@entity1 @entity0 @entity5 @entity3794 @entity281 @entity1410 @entity3 @entity158
OBJECTIVE: To evaluate the safety, cosmesis, and clinical outcome of intraoperative electron radiation therapy (IOERT) delivered prior to lumpectomy for @entity0 . METHODS: From December 2008 to March 2012, 75 @entity0 @entity1 (ages 34-66 years) were treated with IOERT during breast conservative surgery. IOERT was delivered using a mobile linear accelerator. Suitable energy and applicator size were chosen to ensure coverage of the @entity5 with anterior and posterior margins of 1 cm and lateral margins of 2 cm. @entity1 with sentinel node @entity3 or younger than 40 years received 8 Gy as boost followed by post-operative external beam radiation therapy of 50 Gy/25F; the others had 15 Gy, prescribed to the 90% isodose depth. Adjuvant treatment consisted of chemotherapy (55 @entity1 ), hormonal therapy (59 @entity1 ), or combined chemotherapy and hormonal therapy (41 @entity1 ). The safety, cosmesis, and short-term outcome were evaluated. RESULTS: Median follow-up was 54 months (range: 30-66 months). Two (2.7%) @entity1 developed post-surgical @entity1410 . Six (8.0%) @entity1 developed mild @entity0 . Eight (10.7%) @entity1 suffered from @entity158 . One (1.2%) @entity1 experienced a @entity281 . Sixteen (21.3%) @entity1 developed Grade 1 @entity3794 . Forty-three (57.3%) @entity1 had an excellent cosmetic result and 23 (30.7%) had a good cosmetic result. Three @entity1 had an ipsilateral breast recurrence, with an actual 3-year local recurrence rate of 4.0%. One @entity1 had an ipsilateral axillary recurrence, resulting in a 3-year regional recurrence rate of 1.3%. No distant @entity3 or deaths were observed. The 3-year disease free survival was 94.6%. CONCLUSIONS: Intraoperative electron radiation therapy delivered prior to lumpectomy is safe and feasible for selected @entity1 with @entity0 . Early side effects, cosmesis and short-term efficacy are acceptable, but a longer follow-up is needed for evaluation of late side effects and long-term outcome.
